Orakl raises $34 million Series A co-led by Stockholmsnorrskenet and Singular

• Orakl Oncology raised $34 million in an oversubscribed Series A co-led by Stockholmsnorrskenet Management and Singular.
• The round brings total funding to $50 million.
• Orakl combines laboratory-grown patient tumors with AI to predict cancer treatment responses before clinical trials.
• Proceeds will expand its dataset and AI research team, increase data generation fivefold and support expansion into lung and gastric cancers.
• The funding will also establish US and UK teams to deploy predictions across more than 10 drug programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stockholmsnorrskenet Management AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.